Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Delisting risk
confidence 98%
filed 2026-06-05
Research Frontiers received two deficiency notification letters from Nasdaq on June 2, 2026, advising that the Company no longer satisfies the $1.00 minimum bid price requirement and the $35 million minimum Market Value of Listed Securities requirement for continued listing on The Nasdaq Capital Market. The Company has 180 calendar days until November 30, 2026, to regain compliance, with no assurance of success. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-05
Item 3.01
Driven Brands received a notice from Nasdaq on June 1, 2026 that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filing of its 1Q2026 10-Q. The company has 60 calendar days to submit a compliance plan and up to 180 days to regain compliance, with the risk of delisting if it fails to do so.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-04
The filing discloses Item 3.01 notification that Abpro Holdings' securities will be delisted from Nasdaq effective immediately due to failure to meet the minimum equity standard requirement under Nasdaq Listing Rule 5550(b)(1) by the February 16, 2026 deadline. The Nasdaq Listing and Hearing Review Council reaffirmed the delisting decision on May 28, 2026, and the company expects Nasdaq to file a Form 25 to deregister the securities. This is a terminal delisting event with material consequences for trading and liquidity.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-04
Item 3.01
The filing discloses that following the death of director Douglas Maine on June 1, 2026, the Company notified Nasdaq on June 2, 2026 that it is no longer in compliance with three critical Nasdaq Listing Rules: the majority independent director requirement (Rule 5605(b)(1)), the audit committee independence requirement (Rule 5605(c)(2)(A)), and the compensation committee independence requirement (Rule 5605(d)(2)(A)). Although Nasdaq has granted a cure period until the earlier of the next Annual Meeting or May 31, 2027, the filing explicitly states "there can be no assurance that Company will be able to regain compliance with the applicable Nasdaq Listing Rules" within the required timeframe, creating material delisting risk.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-04
The filing discloses that NYSE American accepted Volato's compliance plan on June 3, 2026, following a March 17, 2026 notice of non-compliance with continued listing standards (Sections 1003(a)(i) and 1003(a)(ii)). The company has until December 17, 2026 to regain compliance, with explicit warning that failure to do so or lack of progress "may initiate delisting proceedings." This is a material delisting risk event under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-04
Item 3.01
Smith-Midland received a notice from Nasdaq on May 29, 2026 stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file the Form 10-Q for the quarter ended March 31, 2026. While the notice has no immediate delisting effect, the company faces a July 28, 2026 deadline to file or submit a compliance plan, creating material delisting risk. This is a classic Item 3.01 disclosure of failure to satisfy a continued listing rule.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-06-03
Item 3.01
Fifth Third Bancorp voluntarily transferred its principal listing from Nasdaq to the NYSE, effective June 11-12, 2026. This material corporate action affects the regulatory framework and trading mechanics for the company's securities.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-03
Item 3.01
FONAR notified Nasdaq of its intent to remove the Common Stock from listing, requested suspension of trading prior to June 3, 2026, and intends to file a Form 25 to delist and deregister the Common Stock under Section 12(b) of the Exchange Act, as well as a Form 15 to suspend reporting obligations.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-03
The filing discloses that Reliance Global Group received a Nasdaq delisting notice on December 12, 2025 for failing to maintain the $1.00 minimum bid price requirement, and subsequently regained compliance on June 2, 2026 after the closing bid price remained at or above $1.00 for 10 consecutive business days. This is a material delisting risk event under Item 8.01, as it directly addresses the company's continued listing status on Nasdaq Capital Market under Listing Rule 5550(a)(2).
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-03
Reed's, Inc. received a notice from NYSE American on May 29, 2026 stating non-compliance with continued listing standards under Sections 1003(a)(ii) and 1003(a)(iii) due to insufficient stockholders' equity ($4.0 million and $6.0 million thresholds, respectively) given reported losses in recent fiscal years. The company must submit a compliance plan by June 28, 2026 or face delisting proceedings, with a compliance deadline of November 29, 2027. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-03
Item 3.01
Cardlytics received formal notice from Nasdaq that its stock has closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a delisting compliance notice under Nasdaq Listing Rule 5550(a)(2). The company has 180 days until November 30, 2026 to regain compliance or face delisting.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-02
Item 8.01
The filing discloses that PDS Biotechnology received a deficiency letter from Nasdaq on February 25, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and subsequently regained compliance by June 2, 2026. This is a classic delisting risk disclosure—the company faced potential delisting but has now resolved the non-compliance. The resolution of the matter is material to investors as it confirms the company's continued listing status on Nasdaq.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-02
Item 3.01
Triller disclosed receipt of a Nasdaq exception to regain compliance with the Bid Price Rule (minimum $1.00 closing bid price for 10 consecutive business days by June 30, 2026). This is a delisting risk disclosure under Item 3.01: the company faces potential delisting if it fails to meet the bid price requirement within the specified cure period. The filing also references prior delisting threats (December 2025 decision, April 2026 trading suspension) that were partially resolved, making the current bid price deficiency a material continuing compliance risk.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-06-02
Item 3.01
LendingClub Corp voluntarily withdrew its listing from the NYSE and transferred its listing to Nasdaq, effective June 18–22, 2026, concurrent with a rebranding to Happen, Inc. and a ticker change to 'HAPN'. This material transfer of listing venue affects investor trading access and the company's market profile.
View raw filing on EDGAR →
Delisting risk
confidence 85%
filed 2026-06-02
Item 7.01
The filing discloses material delisting risk through forward-looking statements regarding the Company's ability to continue to comply with NYSE listing standards and maintain the listing of its Class A common stock. The reverse stock split approval is being pursued in part to address potential delisting risk.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-01
Item 3.01
GENCOR Industries received a formal Delinquency Notification from NYSE Regulation on May 19, 2026, for non-compliance with NYSE American continued listing standards due to failure to timely file its Form 10-Q. The company has a six-month cure period, and NYSE may commence suspension and delisting proceedings at any time.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-01
Item 8.01
Leslie's received a Nasdaq delisting notice on February 11, 2026 for failing to maintain the minimum market value of publicly held shares ($15 million) for 30 consecutive business days under Listing Rule 5450(b)(3)(C), with an August 10, 2026 compliance deadline. The May 29, 2026 letter confirms the Company has regained compliance and the matter is closed. This disclosure directly addresses a delisting risk event and its resolution, which is material to investors assessing the registrant's continued listing status.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-01
Item 3.01
Flushing Financial's common stock was suspended from trading on Nasdaq effective June 1, 2026, following notification of the merger completion. The company will be delisted from Nasdaq upon effectiveness of Form 25, and OceanFirst intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-01
The filing discloses Item 3.01 regarding a delisting notice from Nasdaq. Columbus Acquisition Corp received a May 22, 2026 notice that its market value of listed securities (MVLS) fell below the $50 million minimum requirement under Nasdaq Listing Rule 5450(b)(2)(A). Although the company subsequently regained compliance by May 28, 2026, the initial delisting notice and the company's prior non-compliance with continued listing standards is a material event that would affect investor assessment of listing status and trading continuity.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-01
Item 3.01
iSpecimen received a formal notice from Nasdaq on May 29, 2026, that it fails to comply with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2,500,000. The Company reported only $814,038 in stockholders' equity as of March 31, 2026, and does not meet any of the alternative continued listing standards. While the Company has 45 days to submit a compliance plan and potential 180-day extension, the notice represents a material delisting risk that would significantly affect investor assessment of the registrant's continued public trading status.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-01
NusaTrip received a delinquency notification from Nasdaq on May 27, 2026, for failure to timely file its Form 10-K and Form 10-Q, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, or face delisting. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-06-01
The filing discloses Item 3.01 regarding Nasdaq's notice that HCW Biologics failed to maintain the minimum $1 bid price for 30 consecutive business days under Listing Rule 5550(a)(2). While the Nasdaq Hearings Panel granted a conditional extension on May 29, 2026, requiring compliance by July 29, 2026, the company faces immediate delisting if it becomes deficient again before September 22, 2026. This is a material delisting risk event that directly affects the registrant's continued listing status.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-06-01
The filing discloses that Beyond Air received a decision from the Nasdaq Hearings Panel granting continued listing subject to compliance with the Bid Price Rule by July 31, 2026, with a one-year monitoring period. The disclosure explicitly warns that failure to comply or any listing standard violation during the monitoring period will result in a Staff Delisting Determination and suspension of the company's common stock. This is a material delisting risk event under Item 8.01.
View raw filing on EDGAR →
Delisting risk
confidence 85%
filed 2026-06-01
Item 8.01
The disclosure describes a Nasdaq compliance notice under Listing Rule 5250(c)(1) for failure to meet periodic filing requirements, followed by notification of regained compliance. While the matter was resolved, the initial non-compliance notice and delisting risk trigger material disclosure obligations. The company's ability to maintain listing is a material concern to investors, even though compliance was subsequently restored.
View raw filing on EDGAR →
Delisting risk
confidence 85%
filed 2026-06-01
Item 7.01
Exicure received a notification from Nasdaq's Listing Qualifications Department indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filing of its Form 10-Q. Although the company states it has since regained compliance by filing the 10-Q on May 29, 2026, the receipt of a listing compliance notice is a material delisting risk event that would affect a reasonable investor's assessment of the company's continued listing status.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Item 3.01
Gulf Resources received a Nasdaq delisting determination letter on May 26, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for Q1 2026 and Form 10-K for 2025. The company has until June 22, 2026 to submit a compliance plan and until October 12, 2026 to regain compliance, or face delisting. This is a material disclosure of delisting risk that would significantly affect investor assessment of the registrant's continued trading status.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Item 3.01
Aditxt received a formal delisting notice from Nasdaq on May 27, 2026, citing failure to satisfy the minimum stockholders' equity requirement of $2.5 million (the company reported negative equity of $35.2 million). The filing explicitly discloses multiple listing deficiencies—stockholders' equity, minimum bid price, and market value of publicly held shares—and states that the Nasdaq Hearings Panel will determine whether to delist the company's securities. The disclosure directly invokes delisting risk under Item 3.01 and references substantial doubt about going concern, making this a clear and material delisting notice.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Item 3.01
Actinium Pharmaceuticals received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards due to stockholders' equity of $2.3 million falling below the required $4.0 million threshold while reporting net losses in five consecutive fiscal years. The company must submit a compliance plan by June 26, 2026, or face delisting proceedings.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-29
Item 8.01
The filing discloses receipt of a deficiency letter from Nasdaq on April 17, 2026, notifying Expensify that its Class A common stock had fallen below the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Listing Rule 5450(a)(1). Although the Company subsequently regained compliance by May 28, 2026, the initial deficiency notice and the period of non-compliance constitute a material delisting risk event that would affect investor assessment of the registrant's listing status.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Item 3.01
Edible Garden received a notice from Nasdaq on May 27, 2026 that it failed to maintain the minimum $1 bid price required under Nasdaq Listing Rule 5550(a)(2) for at least 30 consecutive business days. The company is ineligible for a compliance period due to prior reverse stock splits exceeding the 250:1 cumulative threshold, and its securities will be suspended from trading on June 5, 2026 unless it successfully appeals to a Nasdaq Hearings Panel by June 3, 2026. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Clean Energy Technologies received a written notice from Nasdaq on May 26, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. The filing explicitly states that if the Company fails to regain compliance, "the Company's securities will be subject to delisting from Nasdaq." This is a classic delisting risk disclosure under Item 3.01, with material consequences including reduced liquidity, market price impact, and impaired access to capital markets.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
HWH International received a notice from Nasdaq on May 29, 2026 indicating non-compliance with the minimum stockholders' equity requirement of $2.5 million under Listing Rule 5550(b)(1), with reported stockholders' equity of only $2,078,220. The company has 45 days to submit a compliance plan and up to 180 days to regain compliance, or face potential delisting. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-29
Item 3.01
Fathom Holdings received a notification letter from Nasdaq on May 22, 2026, indicating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. The company has 60 days to submit a compliance plan and faces potential delisting if it cannot regain compliance. This is a classic delisting-risk disclosure under Item 3.01, as it documents the company's failure to satisfy a continued listing standard and the procedural pathway toward potential delisting.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Item 3.01
Onfolio received a written notice from Nasdaq on May 26, 2026, stating non-compliance with Listing Rule 5550(b)(1) due to stockholders' equity of $1,216,603 falling below the required $2,500,000 minimum. The company also fails to meet alternative continued listing standards. This is a classic delisting risk disclosure under Item 3.01, with a 45-day cure period and potential suspension or delisting if compliance is not achieved.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-29
Item 3.01
Cloudastructure received a notice from Nasdaq on May 26, 2026, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, with explicit acknowledgment that "there is no assurance that Nasdaq will accept the Company's plan to regain compliance." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-28
Item 3.01
Lulu's Fashion Lounge received a Nasdaq notification on May 21, 2026 that it is out of compliance with the minimum $2.5 million stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)), with reported stockholders' equity of approximately $(525) thousand as of March 29, 2026. The company has 45 calendar days to submit a compliance plan and up to 180 days to regain compliance, with no assurance of success. This is a classic delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-28
Item 3.01
American Woodmark notified Nasdaq of the merger closing and requested suspension of trading and withdrawal of its common stock from Nasdaq listing, effective May 29, 2026, with plans to file Form 25 for delisting and Form 15 for deregistration.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-28
Item 8.01
ENDRA received a Nasdaq delisting notice on April 20, 2026, after its stockholders' equity fell below the $2.5 million minimum requirement. The Company requested a hearing before the Nasdaq Hearings Panel, which stayed delisting action, and believes it has regained compliance through the recent securities offering.
View raw filing on EDGAR →
Delisting risk
confidence 92%
filed 2026-05-28
Item 8.01
The filing discloses that Quantum Cyber N.V. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after previously receiving a deficiency notice on March 20, 2026, for failing to maintain a minimum bid price of $1.00 per share. While the current disclosure reports resolution of the delisting risk, the underlying event—the prior non-compliance and threat of delisting—is material to investors' assessment of the company's listing status and financial condition.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-28
Item 3.01
Richtech Robotics received a formal notice from Nasdaq on May 22, 2026, stating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. The Company has been notified that if it fails to regain compliance within the extension period, its securities will be subject to delisting from the Nasdaq Capital Market.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-28
CDT Equity Inc. received a deficiency notice from Nasdaq on May 21, 2026, for failure to comply with Nasdaq Listing Rule 5250(c)(1) due to untimely filing of its Form 10-Q for Q1 2026. The company has until July 20, 2026, to submit a compliance plan. This is a classic delisting risk disclosure under Item 3.01, indicating the company's securities are at risk of being delisted from The Nasdaq Capital Market if compliance is not regained.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-27
Item 3.01
Medicus Pharma received written notice from Nasdaq on May 20, 2026, that it failed to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35,000,000 for 30 consecutive business days and does not satisfy alternative listing standards. The company has 180 days until November 16, 2026, to regain compliance or face delisting.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-27
Item 3.01
Liminatus Pharma received notice from Nasdaq on May 20, 2026 that it failed to regain compliance with the MVLS Rule and MVPHS Rule by the May 18, 2026 deadline, resulting in delisting from The Nasdaq Global Market effective May 29, 2026 unless an appeal is granted. The company requested an appeal on May 26, 2026, which stays the delisting pending a hearing. This is a clear delisting notice under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-27
Item 3.01
The NYSE suspended trading and delisted Veris Residential's shares on May 27, 2026, in connection with the merger consummation. The NYSE filed Form 25 to report the delisting and effect deregistration under Section 12(b) of the Exchange Act, and the Company intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-27
Item 8.01
Jaguar Health regained compliance with Nasdaq's Bid Price Rule (Listing Rule 5550(a)(2)) as of May 26, 2026, but remains subject to a mandatory one-year Panel Monitor period with a critical condition: failure to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days would result in immediate delisting without the standard 180-day grace period.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-27
Item 3.01
ASPAC III received a notice from Nasdaq on May 20, 2026 stating that stockholders' equity fell below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1), resulting in non-compliance with continued listing standards. The company has 45 days to submit a compliance plan and up to 180 days to evidence compliance, with no assurance of success. This is a direct delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 96%
filed 2026-05-27
Item 3.01
Borealis Foods received a notice from Nasdaq on May 21, 2026 stating that the Company no longer complies with Nasdaq Listing Rule 5250(c)(1) due to failure to timely file the Q1 2026 Form 10-Q. The Company has until June 16, 2026 to submit a compliance plan and until October 12, 2026 to regain compliance.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-27
Item 3.01
Charlton Aria received a Notice from Nasdaq on May 22, 2026, for non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Form 10-Q for the period ended March 31, 2026. This is a second notice following an earlier April 16, 2026 notice regarding failure to file the Form 10-K. The company has until June 15, 2026 to file the required reports or submit a compliance plan, with potential delisting consequences.
View raw filing on EDGAR →
Delisting risk
confidence 95%
filed 2026-05-27
Item 3.01
SOBR Safe received a Nasdaq deficiency letter on March 19, 2026 for failing to maintain the $1.00 minimum bid price requirement for 30 consecutive business days. Although the company obtained a stay and a conditional extension until September 15, 2026 to regain compliance (contingent on completing a business combination with Clean World Ventures and demonstrating compliance with Initial Listing Rules), the filing explicitly discloses the delisting risk and the conditions precedent to continued listing, which is the core substance of Item 3.01.
View raw filing on EDGAR →
Delisting risk
confidence 98%
filed 2026-05-27
SINTX received a notice from Nasdaq on May 22, 2026 (Item 3.01) stating the company is not in compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. The company reported only $904,000 in stockholders' equity as of March 31, 2026 and does not meet alternative listing standards. The company has 45 days to submit a compliance plan or faces delisting risk, making this a material disclosure of continued listing failure under Item 3.01.
View raw filing on EDGAR →